Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis

National Cancer Institute Surveillance Epidemiology and End Results Program Mikhael, 2019, Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline, J Clin Oncol, 37, 1228, 10.1200/JCO.18.02096 Mikhael, 2019, Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline, J Clin Oncol, 37, 1228, 10.1200/JCO.18.02096 Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations, Ann Intern Med, 162, 777, 10.7326/M14-2385 Cleo, 2019, Usability and acceptability of four systematic review automation software packages: a mixed method design, Syst Rev, 8, 145, 10.1186/s13643-019-1069-6 Higgins, 2011, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 Guyot, 2012, Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves, BMC Med Res Methodol, 12, 9, 10.1186/1471-2288-12-9 Durie, 2006, International uniform response criteria for multiple myeloma, Leukemia, 20, 1467, 10.1038/sj.leu.2404284 Gelman, 1992, Inference from iterative simulation using multiple sequences, Stat Sci, 7, 457, 10.1214/ss/1177011136 Dias, 2010, Checking consistency in mixed treatment comparison meta-analysis, Stat Med, 29, 932, 10.1002/sim.3767 Lin, 2017, Performing arm-based network meta-analysis in R with the pcnetmeta package, J Stat Softw, 80, 10.18637/jss.v080.i05 Hong, 2016, A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons, Res Synth Methods, 7, 6, 10.1002/jrsm.1153 Salanti, 2011, Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial, J Clin Epidemiol, 64, 163, 10.1016/j.jclinepi.2010.03.016 Sacchi, 2011, A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant, Leuk Lymphoma, 52, 1942, 10.3109/10428194.2011.584006 San-Miguel, 2014, Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma, Blood, 123, 4136, 10.1182/blood-2013-12-546374 Mateos, 2016, Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM, Blood, 127, 420, 10.1182/blood-2015-08-666537 Beksac, 2011, Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group, Eur J Haematol, 86, 16, 10.1111/j.1600-0609.2010.01524.x Hulin, 2009, Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial, J Clin Oncol, 27, 3664, 10.1200/JCO.2008.21.0948 Durie, 2017, Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial, Lancet, 389, 519, 10.1016/S0140-6736(16)31594-X Facon, 2007, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial, Lancet, 370, 1209, 10.1016/S0140-6736(07)61537-2 Palumbo, 2006, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial, Lancet, 367, 825, 10.1016/S0140-6736(06)68338-4 Waage, 2010, Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma, Blood, 116, 1405, 10.1182/blood-2009-08-237974 Wijermans, 2010, Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study, J Clin Oncol, 28, 3160, 10.1200/JCO.2009.26.1610 Stewart, 2015, Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma, Blood, 126, 1294, 10.1182/blood-2014-12-613927 Zweegman, 2016, Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma, Blood, 127, 1109, 10.1182/blood-2015-11-679415 Hungria, 2016, Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible, Ann Hematol, 95, 271, 10.1007/s00277-015-2537-2 Morgan, 2011, Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation, Blood, 118, 1231, 10.1182/blood-2011-02-338665 Magarotto, 2016, Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma, Blood, 127, 1102, 10.1182/blood-2015-08-662627 Benboubker, 2014, Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma, N Engl J Med, 371, 906, 10.1056/NEJMoa1402551 Zonder, 2010, Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232), Blood, 116, 5838, 10.1182/blood-2010-08-303487 Mateos, 2020, Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial, Lancet, 395, 132, 10.1016/S0140-6736(19)32956-3 Weisel, 2017, A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation, Leuk Lymphoma, 58, 153, 10.1080/10428194.2016.1177772 Mateos, 2018, Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma, N Engl J Med, 378, 518, 10.1056/NEJMoa1714678 Blommestein, 2019, Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis, Haematologica, 104, 1026, 10.3324/haematol.2018.206912 Facon, 2019, Daratumumab plus lenalidomide and dexamethasone for untreated myeloma, N Engl J Med, 380, 2104, 10.1056/NEJMoa1817249 Zweegman, 2019, Frailty in multiple myeloma: the need for harmony to prevent doing harm, Lancet Haematol, 6, e117, 10.1016/S2352-3026(19)30011-0 Palumbo, 2015, Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report, Blood, 125, 2068, 10.1182/blood-2014-12-615187 Engelhardt, 2017, A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients, Haematologica, 102, 910, 10.3324/haematol.2016.162693